AASM. (2005). The International Classification of Sleep Disorders: diagnostic and coding manual. 2nd Ed. Westchester, IL: AASM.
Akintomide, G. S., &; Rickards, H. (2011). Narcolepsy: a review. Neuropsychiatr Dis Treat, 7, 507-518.
Anic-Labat, C., Guilleminault, C., Kraemer, H., Meehan, J., Arrigoni, J., &; Mignot, E. (1999). Validation of a Cataplexy Questionnaire in 983 Sleep-disorders Patients. Sleep, 19, 77-87.
Albert, W., Hudalla, A., Traue, K., &; Hetzer, R. (2012). Impact of heart transplantation in infancy and adolescence on quality of life and compliance. HSR Proc Intensive Care Cardiovasc Anesth, 4(2), 125-129.
Aldrich, M. S. (1998). Diagnostic aspects of narcolepsy. [Review]. Neurology, 50(2 Suppl 1), S2-7.
Allen, M. D., Hedges, D. W., Farrer, T. J., &; Larson, M. J. (2012). Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. [Case Reports]. Neurocase, 18(1), 13-25.
Andlauer, O., Moore, H. t., Hong, S. C., Dauvilliers, Y., Kanbayashi, T., Nishino, S., . . . Mignot, E. (2012). Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep, 35(9), 1247-1255F.
Ando, A., Shigenari, A., Naruse, T. K., Sugaya, K., Juji, T., Honda, Y., Inoko, H. (1997). Triplet repeat polymorphism within the NOTCH4 gene located near the junction of the HLA class II and class III regions in narcolepsy. Tissue Antigens, 50(6), 646-649.
Arii, J., Kanbayashi, T., Tanabe, Y., Sawaishi, Y., Kimura, S., Watanabe, A., Nishino, S. (2004). CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. [Review]. Neurology, 63(12), 2440-2442.
Baier, P. C., Hallschmid, M., Seeck-Hirschner, M., Weinhold, S. L., Burkert, S., Diessner, N., . . . Hinze-Selch, D. (2011). Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Medicine, 12(10), 941-946.
Bajaj J. S. (2008) Minimal hepatic encephalopathy matters in daily life. World Journal Gastroenterol. 14(23): 3609–3615.
Bassetti, C., &; Aldrich, M. S. (1996). Narcolepsy. [Review]. Neurology Clinic, 14(3), 545-571.
Baumann, C. R., Khatami, R., Werth, E., &; Bassetti, C. L. (2006). Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. Journal of Neurol Neurosurg Psychiatry, 77(3), 402-404.
Bayard, S., Abril, B., Yu, H., Scholz, S., Carlander, B., &; Dauvilliers, Y. (2011). Decision Making in Narcolepsy with Cataplexy. SLEEP, 34(1), 99-104.
Bayard, S., Croisier Langenier, M., Cochen De Cock, V., Scholz, S., &; Dauvilliers, Y. (2012). Executive control of attention in narcolepsy. PLoS One, 7(4), e33525.
Becker, P. M., Schwartz, J. R., Feldman, N. T., &; Hughes, R. J. (2004). Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berl), 171(2), 133-139.
Bernardini, C., Lattanzi, W., Bosco, P., Franceschini, C., Plazzi, G., Michetti, F., &; Ferri, R. (2012). Genome-wide gene expression profiling of human narcolepsy. Gene Express, 15(4), 171-181.
Berry, R. B. (2012). Fundamental of Sleep Medicineicine. Philadelphia, PA: Elsevier.
Berton, D. C., Silveira, L., Da Costa, C. C., De Souza, R. M., Winter, C. D., &; Zimermann Teixeira, P. J. (2013). Effectiveness of Pulmonary Rehabilitation in Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease Patients With and Without Global Fat-Free Mass Depletion. Arch Phys Medicine Rehabil.
Beusterien, K. M., Rogers, A. E., Walsleben, J. A., Emsellem, H. A., Reblando, J. A., Wang, L., Steinwald, B. (1999). Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep, 22(6), 757-765.
Black, J., &; Guilleminault, C. (2001). Medicineications for the treatment of narcolepsy. Expert Opin Emerg Drugs, 6(2), 239-247.
Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S., &; Roth, B. (1981). Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can Journal of Neurology Science, 8(4), 299-304.
Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S., &; Roth, B. (1983). Life effects of narcolepsy: relationships to geographic origin (North American, Asian or European) and to other patient and illness variables. Journal of Neurology Science, 10(2), 100-104.
Broughton, R. J. (1992). Psychosocial impact of Narcolepsy with Cataplexy with Comparisons to Idoiopathic Hypersomnia and Epilepsy. USA, NY.: Haworth Press.
Bruck, D. (2001). The impact of narcolepsy on psychological health and role behaviours: negative effects and comparisons with other illness groups. Sleep Medicine, 2(5), 437-446.
Brown, T. E., &; Landgraf, J. M. (2010). Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. [Randomized Controlled Trial]. Postgrad Medicine, 122(5), 42-51.
Campbell, A. J., Signal, T. L., O'Keeffe, K. M., &; Bakker, J. P. (2011). Narcolepsy in New Zealand: pathway to diagnosis and effect on quality of life.. MedicineJournal, 124(1336), 51-61.
Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR,Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standardmeasure of sleepiness. Sleep 1986;9:519-524.Cao, M. (2010). Advances in narcolepsy. [Review]. Medicine Clinic North American, 94(3), 541-555.
Challamel, M. J., Mazzola, M. E., Nevsimalova, S., Cannard, C., Louis, J., &; Revol, M. (1994). Narcolepsy in children. [Comparative Study]. Sleep, 17(8 Suppl), S17-20.
Chen, G., Zhou, X., Hu, X., Liu, Y., &; Li, Q. (2011). [Effect of exercise on the quality of life and pulmonary function in patients with chronic obstructive pulmonary disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 36(7), 682-686.
Coelho, F. M., Pradella-Hallinan, M., Predazzoli Neto, M., Bittencourt, L. R., &; Tufik, S. (2009). Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in Sao Paulo. Review Bras Psiquiatr, 31(1), 10-14.
Golicki, D., Bala, M. M., Niewada, M., &; Wierzbicka, A. (2010). Modafinil for narcolepsy: systematic review and meta-analysis. Medicine Science Monit, 16(8), RA177-186.
Cortesi, P. A., Mencacci, C., Luigi, F., Pirfo, E., Berto, P., Sturkenboom, M. C., . . . Scalone, L. (2013). Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry, 13, 98. vol: 10.1186
Dahlitz, M., Vaughan, R., Kayed, K., &; Parkes, J. D. (1992). The narcolepsy susceptibility gene. Lancet, 339(8804), 1297.
Dalal, M. A., Schuld, A., &; Pollmacher, T. (2002). Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy. Journal ofSleep Res, 11(3), 273.
Daniels, E., King, M. A., Smith, I. E., &; Shneerson, J. M. (2001). Health-related quality of life in narcolepsy. Journal Sleep Research, 10(1), 75-81.
Dauvilliers, Y., Montplaisir, J., Molinari, N., Carlander, B., Ondze, B., Besset, A., &; Billiard, M. (2001). Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology, 57(11), 2029-2033.
David, A., Constantino, F., dos Santos, J. M., &; Paiva, T. (2012). Health-related quality of life in Portuguese patients with narcolepsy. Sleep Medicine, 13(3), 273-277. do
Delazer, M., Hogl, B., Zamarian, L., Wenter, J., Gschliesser, V., Ehrmann, L., Frauscher, B. (2011). Executive functions, information sampling, and decision making in narcolepsy with cataplexy. Neuropsychology, 25(4), 477-487.
Dickson, A., Toft, A., &; O'Carroll, R. E. (2009). Neuropsychological functioning, illness perception, mood and quality of life in chronic fatigue syndrome, autoimmune thyroid disease and healthy participants. PsychologyMedicine, 39(9), 1567-1576.
Dimitrova, A., Fronczek, R., Van der Ploeg, J., Scammell, T., Gautam, S., Pascual-Leone, A., &; Lammers, G. J. (2011). Reward-seeking behavior in human narcolepsy. JournalClinical Sleep Medicine, 7(3), 293-300.
Dodel, R., Peter, H., Spottke, A., Noelker, C., Althaus, A., Siebert, U.,Mayer, G. (2007). Health-related quality of life in patients with narcolepsy. Sleep Medicine, 8(7-8), 733-741
Doherty, L., Crowe, C., &; Sweeney, B. (2010). National narcolepsy survey. Ir MedicineJournal, 103(4), 110, 112-113.
Droogleever Fortuyn, H. A., Fronczek, R., Smitshoek, M., Overeem, S., Lappenschaar, M., Kalkman, J.,Bleijenberg, G. (2012). Severe fatigue in narcolepsy with cataplexy. Journal Sleep Research, 21(2), 163-169.
Feldman, G. J. (2013). Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol. Int Journal Chron Obstruct Pulmon Dis, 8, 89-96.
Ferrans, C. E. (1990). Quality of life: conceptual issues. Semin Oncology Nursery, 6(4), 248-254.
Ferrans, C. E., &; Powers, M. J. (1992). Psychometric assessment of the Quality of Life Index. Research Nursery Health, 15(1), 29-38.
Finkel, S. E. (1995). Causal analysis with panel data. CA: Sage Publications.
Fortuyn, H. A., Swinkels, S., Buitelaar, J., Renier, W. O., Furer, J. W., Rijnders, C. A., Overeem, S. (2008). High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep, 31(3), 335-341.
Fronczek, R., Middelkoop, H. A., van Dijk, J. G., &; Lammers, G. J. (2006). Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). Sleep, 29(2), 187-191.
Fronczek, R., Raymann, R. J., Romeijn, N., Overeem, S., Fischer, M., van Dijk, J. G., Van Someren, E. J. (2008). Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep, 31(2), 233-240.
George, C. F., Boudreau, A. C., &; Smiley, A. (1996). Comparison of simulated driving performance in narcolepsy and sleep apnea patients. Sleep, 19(9), 711-717.
Gigliotti, F., Grazzini, M., Stendardi, L., Romagnoli, I., &; Scano, G. (2002). Quality of life and functional parameters in patients with chronic obstructive pulmonary disease (COPD): an update. [Review]. RespiratoryMedicine, 96(6), 373-374.
Guilleminault, C. (1993). Amphetamines and narcolepsy: use of the Stanford database. Sleep, 16(3), 199-201.
Guilleminault, C., Billiard, M., Montplaisir, J., &; Dement, W. (1975). Altered states of consciousness in disorder of daytime sleepiness. Journal of Neuro-Science., 26, 377-393.
Guilleminault, C., Mignot, E., Aldrich, M., Quera-Salva, M. A., Tiberge, M., &; Partinen, M. (1988). Prazosin contraindicated in patients with narcolepsy. Lancet, 2(8609), 511.
Han, F., Chen, E. Z., Wei, H. L., Dong, X. S., Li, J., Li, M., Ding, D. J. (2003). [HLA-DRB and -DQB allele contribution to narcolepsy susceptibility in Chinese patients with narcolepsy]. Zhonghua Yi Xue Za Zhi, 83(8), 644-646.
Hara, J., Beuckmann, C. T., Nambu, T., Willie, J. T., Chemelli, R. M., Sinton, C. M., Sakurai, T. (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron, 30(2), 345-354.
Harsh, J. R., Hayduk, R., Rosenberg, R., Wesnes, K. A., Walsh, J. K., Arora, S., Roth, T. (2006). The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. CurrentMedicine Research Opinuon, 22(4), 761-774.
Hsiao, C. (1989). Analysis of panel data.: Cambridge University Press.
Huang, Y. S., &; Guilleminault, C. (2009). Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurolohy, 41(1), 9-16. doi: 10.1016/j.pediatrneurol.2009.02.008
Huda, M. S., Mani, H., Durham, B. H., Dovey, T. M., Halford, J. C., Aditya, B. S., Hart, I. K. (2013). Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. Endocrine, 43(3), 696-704.
Hungs, M., &; Mignot, E. (2001). Hypocretin/orexin, sleep and narcolepsy. Bioessays, 23(5), 397-408. doi: 10.1002/bies.1058
Jacobsen, P. B., &; Jim, H. S. (2011). Consideration of quality of life in cancer survivorship research. [Review]. Cancer Epidemiol Biomarkers Prev, 20(10), 2035-2041.
Johns, M. W. (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, 14(6), 540-545.
Johns, M. W. (1992). Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep, 15(4), 376-381.
Johns, M. W. (1993). Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest, 103(1), 30-36.
Johns, M. W. (1994). Sleepiness in different situations measured by the Epworth Sleepiness Scale. [Comparative Study]. Sleep, 17(8), 703-710.
Joo, E. Y., Seo, D. W., Tae, W. S., &; Hong, S. B. (2008). Effect of modafinil on cerebral blood flow in narcolepsy patients. Sleep, 31(6), 868-873.
Juji, T., Satake, M., Honda, Y., &; Doi, Y. (1984). HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. [Comparative Study]. Tissue Antigens, 24(5), 316-319.
Kales, A., Soldatos, C. R., Bixler, E. O., Caldwell, A., Cadieux, R. J., Verrechio, J. M., &; Kales, J. D. (1982). Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology. Arch Neurology, 39(3), 169-171.
Krahn, L. E., Pankratz, V. S., Oliver, L., Boeve, B. F., &; Silber, M. H. (2002). Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep, 25(7), 733-736.
Kawashima, M., Lin, L., Tanaka, S., Jennum, P., Knudsen, S., Nevsimalova, S., . . . Mignot, E. (2010). Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep, 33(7), 869-874.
Klein, G., Burghaus, L., &; Diederich, N. (2012). [Pathogenesis of narcolepsy: from HLA association to hypocretin deficiency]. [Review]. Fortschr Neurology Psychiatry, 80(11), 627-634.
Kornum, B. R., Faraco, J., &; Mignot, E. (2011). Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. [Review]. Curr Opin Neurobioogyl, 21(6), 897-903.
Krahn, L. E., Pankratz, V. S., Oliver, L., Boeve, B. F., &; Silber, M. H. (2002). Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep, 25(7), 733-736.
Lim, A. S., &; Scammell, T. E. (2010). The trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy? [Comment]. Sleep, 33(7), 857-858.
Lecendreux, M., Bruni, O., Franco, P., Gringras, P., Konofal, E., Nevsimalova, S.,Poli, F. (2012). Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. Journal Sleep Research, 21(4), 481-483.
Longstreth, W. T., Jr., Koepsell, T. D., Ton, T. G., Hendrickson, A. F., &; van Belle, G. (2007). The epidemiology of narcolepsy. Sleep, 30(1), 13-26.
Mignot, E., Guilleminault, C., Bowersox, S., Frusthofer, B., Nishino, S., Maddaluno, J., Dement, W. C. (1989). Central alpha 1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep. Brain Research, 490(1), 186-191.
Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., &; Dement, W. C. (1988). Effect of alpha 1-adrenoceptors blockade with prazosin in canine narcolepsy. Brain Research, 444(1), 184-188.
Mitler, M. M., Harsh, J., Hirshkowitz, M., &; Guilleminault, C. (2000). Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Medicine, 1(3), 231-243.
Moreno-Iniguez, M., Ortuno, F., Arbizu, J., Millan, M., Soutullo, C., &; Cervera-Enguix, S. (2005). Regional cerebral blood flow SPECT study, at rest and during Wisconsin Card Sorting Test (WCST) performance, in schizophrenia naive patients or treated with atypical neuroleptics. Actas Esp Psiquiatr, 33(6), 343-351.
Moreira, F., Pedrazzoli, M., Dos Santos Coelho, F. M., Pradella-Hallinan, M., Lopes da Conceicao, M. C., Pereira Peregrino, A. J.,Tufik, S. (2005). Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients. Brain Res Mol Brain Research, 140(1-2), 150-154.
Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis ofnarcolepsy and narcolepsy's borderland. Neurology 1993;43:55-60.
Muntner, P., Sudre, P., &; Perneger, T. V. (2000). Comparison of the psychometric properties of the Asthma Quality of life Questionnaire (AQLQ) among 115 asthmatic adults assessed during acute hospitalization and as outpatients. . Quality Life Research, 9(9), 987-995.
Nakamura, M., Kanbayashi, T., Sugiura, T., &; Inoue, Y. (2011). Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. Journal Sleep Research, 20(1 Pt 1), 45-49.
Naumann, A., Bellebaum, C., &; Daum, I. (2006). Cognitive deficits in narcolepsy. JournalSleep Research. 15, 329-338.
Nevsimalova, S. (2009). Narcolepsy in childhood. Sleep Medicine Review, 13(2), 169-180.
Nevsimalova, S., Jara, C., Prihodova, I., Kemlink, D., Sonka, K., &; Skibova, J. (2011). Clinical features of childhood narcolepsy. Can cataplexy be foretold? Eur Journal Paediatr Neurol, 15(4), 320-325.
Nishino, S., Okuro, M., Kotorii, N., Anegawa, E., Ishimaru, Y., Matsumura, M., &; Kanbayashi, T. (2010). Hypocretin/orexin and narcolepsy: new basic and clinical insights.(Oxford), 198(3), 209-222.
Ohayon, M. M., Priest, R. G., Zulley, J., Smirne, S., &; Paiva, T. (2002). Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology, 58(12), 1826-1833.
Olerup, O., Schaffer, M., Hillert, J., &; Sachs, C. (1990). The narcolepsy-associated DRw15,DQw6,Dw2 haplotype has no unique HLA-DQA or -DQB restriction fragments and does not extend to the HLA-DP subregion. Immunogenetics, 32(1), 41-44.
Overeem, S., van Nues, S. J., van der Zande, W. L., Donjacour, C. E., van Mierlo, P., &; Lammers, G. J. (2011). The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Medicine, 12(1), 12-18.
Ozaki, A., Inoue, Y., Hayashida, K., Nakajima, T., Honda, M., Usui, A., Takahashi, K. (2012). Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-naive patients and the general Japanese population. Sleep Medicine, 13(2), 200-206.
Ozaki, A., Inoue, Y., Nakajima, T., Hayashida, K., Honda, M., Komada, Y., &; Takahashi, K. (2008). Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Medicine, 4(6), 572-578.
Palaia, V., Poli, F., Pizza, F., Antelmi, E., Franceschini, C., Moghadam, K. K., . . . Plazzi, G. (2011). Narcolepsy with Cataplexy Associated with Nocturnal Compulsive Behaviors:A Case-Control Study. Sleep., 34(10). 1365-1371.
Pedersen, A., Wilmsmeier, A., Wiedl, K. H., Bauer, J., Kueppers, K., Koelkebeck, K., Ohrmann, P. (2012). Anterior cingulate cortex activation is related to learning potential on the WCST in schizophrenia patients. Brain Cognition, 79(3), 245-251.
Peraita-Adrados, R., Ezpeleta, D., Balas, A., &; Vicario, J. L. (1999). Narcolepsy-cataplexy syndrome associated with DRB1*0806-DQB*0602 haplotype in a Caucasian patient. Sleep Research Online, 2(2), 29-31.
Perneger, T. V., &; Hudelson, P. M. (1995). The quality of quality-of-life measurements. JAMA, 273(11), 843-844.
Planelles, D., Puig, N., Beneto, A., Gomez, E., Rubio, P., Mirabet, V., Montoro, J. A. (1997). HLA-DQA, -DQB and -DRB allele contribution to narcolepsy susceptibility. EuropJournalImmunogenet, 24(6), 409-421.
Ray, K. (2010). Sleep: Narcolepsy--a role for TRIB2 autoantibodies? [Comment]. Nat Review Neurology, 6(5), 238.
Riccioni, G., Prencipe, G., Benvenuto, A., Masciocco, L., Ventra, S., Rizzo, U., Speziale, G. (2013). Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers. Pharmacology, 91(1-2), 35-38.
Rieger, M., Mayer, G., &; Gauggel, S. (2003). Attention deficits in patients with narcolepsy. Sleep, 26(1), 36-43.
Rovere, H., Rossini, S., &; Reimao, R. (2008). Quality of life in patients with narcolepsy: a WHOQOL-bref study. Arq Neuropsiquiatr, 66(2A), 163-167.
Ruiz-Diaz, M., Hernandez-Gonzalez, M., Guevara, M. A., Amezcua, C., &; Agmo, A. (2012). Prefrontal EEG correlation during Tower of Hanoi and WCST performance: effect of emotional visual stimuli. Journal Sex Medicine, 9(10), 2631-2640.
Sanna G, Petralia G, Cossu Rocca M, Marenghi C, Nolè F. (2008) Long Survival in a Patient with Brain Metastases from Breast Cancer.Clinical Medicineicine: Oncology Vol.2 P.103–108
Schoemaker, K., Bunte, T., Wiebe, S. A., Espy, K. A., Dekovic, M., &; Matthys, W. (2012). Executive function deficits in preschool children with ADHD and DBD. [Comparative Study]. Journal Child Psychol Psychiatry, 53(2), 111-119.
Schulz, H., &; Wild-Frenz, J. (1995). The disturbance of cognitive processes in narcolepsy. Journal of Sleep Research., 4, 10-14.
Schwartz, J. R., Nelson, M. T., Schwartz, E. R., &; Hughes, R. J. (2004). Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clinical Neuropharmacol, 27(2), 74-79.
Shin, Y. K., Yoon, I. Y., Han, E. K., No, Y. M., Hong, M. C., Yun, Y. D., Hong, S. C. (2008). Prevalence of narcolepsy-cataplexy in Korean adolescents. Acta Neurology Scand, 117(4), 273-278. doi: 10.1111/j.1600-0404.2007.00930.x
Siegel, J. M., Moore, R., Thannickal, T., &; Nienhuis, R. (2001). A brief history of hypocretin/orexin and narcolepsy. Neuropsychopharmacology, 25(5 Suppl), S14-20.
Solon, G. (1989). The value of panel data in economic research. New York: John Wiley &; Sons, Inc.
Stores, G., Montgomery, P., &; Wiggs, L. (2006). The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin.Pediatrics, 118(4), e1116-1123.
Teixeira VG, Faccenda JF, Douglas NJ. Functional status inpatients with narcolepsy. Sleep Medicine 2004;5(5):477–83.
Vignatelli, L., D'Alessandro, R., Mosconi, P., Ferini-Strambi, L., Guidolin, L., De Vincentiis, A., &; Plazzi, G. (2004). Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. Sleep Medicine, 5(5), 467-475.
Vignatelli, L., Plazzi, G., Peschechera, F., Delaj, L., &; D'Alessandro, R. (2011). A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Medicine, 12(1), 19-23.
Volz, H. P., Gaser, C., Hager, F., Rzanny, R., Mentzel, H. J., Kreitschmann-Andermahr, I., Sauer, H. (1997). Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test--a functional MRI study on healthy volunteers and schizophrenics. . Psychiatry Research, 75(3), 145-157.
Wasserfallen, J. B., Halabi, G., Saudan, P., Perneger, T., Feldman, H. I., Martin, P. Y., &; Wauters, J. P. (2004). Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant, 19(6), 1594-1599.
Watson, N. F., Ton, T. G., Koepsell, T. D., Gersuk, V. H., &; Longstreth, W. T., Jr. (2010). Does narcolepsy symptom severity vary according to HLA-DQB1*0602 allele status? Sleep, 33(1), 29-35.
Wieczorek, S., Dahmen, N., Kasten, M., Epplen, J. T., &; Gencik, M. (2004). A rare form of narcolepsy (HLA-DR2-) shows possible association with (functionally relevant) alpha-interferon gene polymorphisms. Psychiatry Genet, 14(1), 47-51.
Wilson, S. J., Frazer, D. W., Lawrence, J. A., &; Bladin, P. F. (2007). Psychosocial adjustment following relief of chronic narcolepsy. Sleep Medicine, 8(3), 252-259.
王拔群、李學禹、莊銘隆、黃玉書、陳彥宏、邱國樑、陳濘宏 (2003) 中文版Epworth嗜睡量表之信效度研究. 臺灣精神醫學, 17:1, 14-22.吳齊殷、張明宜、陳怡蒨 (2008) 尋找機制與過程:長期追蹤研究的功用. 量化研究學刊, 第二卷(一), 1-26.
邱皓政(2007)脈絡變數的多層次潛在變數模式分析。中華心理學刊。49卷,4期,383-405
郭志剛 (2008) 階層線性模式. Taipei, Taiwan: 五南出版社.
盧瑞芬、曾旭民、蔡益堅 (2003) 國人生活品質評量(I):SF-36台灣版的發展及心理計劃特質分析. 台灣公共衛生雜誌, 22(6), 501-511.曾旭民、盧瑞芬、蔡益堅(2003)國人生活品質評量(Ⅱ):SF-36台灣版的常模與效度檢測. 台灣公共衛生雜誌, Vol.22 No.6. P.512-518